Moreover, PD-L1 has been reported to promote homologous recombination repair by interacting with BRCA1, which subsequently affects cell sensitivity to PARP inhibitors, thus contributing to chemoresistance.18 Notably, recent findings indicate that more than 50% of AM patients exhibit PD-L1 expression, indicating a role for PD-L1 in AM pathogenesis.19,20 However, the specific intrinsic roles of PD-L1 in the growth and recurrence of AM, as well as the underlying mechanisms, remain largely unexplored. Here, BRCA1 is linked to acute myeloblastic leukemia with maturation.